Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

OBI-3424

Generic Name: OBI-3424

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₄O_₆P

CAS Number: 2097713-68-1

Unique Ingredient Identifier: X6SH5T8H76

Overview

OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Phase 1

Active, not recruiting

Posted: 2024/02/02

Sponsor:

Ascentawits Pharmace...

ID:NCT06239155

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Phase 2

Recruiting

Posted: 2020/03/19

Sponsor:SWOG Cancer Research...

ID:NCT04315324

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Phase 1

Terminated

Posted: 2018/07/19

Sponsor:OBI Pharma, Inc

ID:NCT03592264

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

OBI Pharma's Novel TROP2 ADC OBI-902 Receives FDA IND Clearance for Phase 1/2 Trial Using Proprietary GlycOBI® Technology

a month ago

OBI Pharma announced FDA clearance of its IND application for OBI-902, a novel TROP2-targeting antibody-drug conjugate utilizing their proprietary GlycOBI® technology platform, with patient enrollment for Phase 1/2 trials expected in the second half of 2025.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy